<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02037997</url>
  </required_header>
  <id_info>
    <org_study_id>CJH-Erlotinib-2013</org_study_id>
    <nct_id>NCT02037997</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC</brief_title>
  <official_title>Chemotherapy in Combination With Erlotinib, or Sequential Chemotherapy for Erlotinib for Treatment, EGFR - TKI Resistance of EGFR Mutations in Patients With NSCLC Randomized Controlled Phase II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare safety and effectiveness of Chemotherapy
      in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With EGFR -
      TKI Resistance of EGFR Mutations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      from the first cycle of treatment (day one) to two month after the last cycle
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>combination with Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150mg qd combination with docetaxel 75mg/m2 or pemetrexed 500mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sequential chemotherapy for Erlotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel 75mg/m2 or pemetrexed 500mg/m2，after PD，Erlotinib 150mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>docetaxel 75mg/m2 ivgtt D1</description>
    <arm_group_label>combination with Erlotinib</arm_group_label>
    <arm_group_label>sequential chemotherapy for Erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>pemetrexed 500mg/m2 ivgtt D1</description>
    <arm_group_label>combination with Erlotinib</arm_group_label>
    <arm_group_label>sequential chemotherapy for Erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150mg qd</description>
    <arm_group_label>combination with Erlotinib</arm_group_label>
    <arm_group_label>sequential chemotherapy for Erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sign the informed consent

          2. ≥18 years

          3. According to RECIST 1.1 standard, at least one measurable lesions

          4. Histology and cytology confirmed with unfavorable surgical locally advanced stage
             (stage IIIB) or metastatic NSCLC (IV), Sensitive EGFR gene mutation

          5. Palliative treatment has received two medicine first-line platinum-based chemotherapy
             and EGFR - TKI second-line treatment and objective clinical benefit (CR, PR or SD is
             more than 6 months), RESIST standard curative effect evaluation for progress

          6. PS=0,1,2

          7. No serious blood, heart, lung, liver and kidney dysfunction, and immune deficiency

          8. Hb≥9g/dL；WBC≥3*109/L，ANC≥1.5*109/L，PLT≥75*109/L

          9. Men or women of childbearing age in the experiment are willing to take contraceptive
             measures

         10. Estimated survival period for 3 months or more

        Exclusion Criteria:

          1. The palliative chemotherapy ever use docetaxel and pemetrexed

          2. small cell lung cancer non small cell hybrid

          3. Women during pregnancy or lactation

          4. In the past the anti-tumor treatment of any outstanding ease of &gt; CTCAE 2 levels of
             toxicity

          5. Ccr&lt;30 ml/min (calculated by Cockcroft-Gault formula)

          6. hepatic insufficiency： Tbil&gt; 1.5×ULN ALT and AST &gt; 2.5×ULN (Patients with liver
             metastasis&gt;5×ULN) Alkaline phosphatase＞2.5 ×ULN(Patients with liver metastasis&gt;5×ULN)

          7. Severe symptomatic heart disease

          8. Symptomatic brain metastases

          9. In the last 5 years have been or are suffering from other histological types of
             malignant tumor

         10. There are serious or uncontrolled systemic diseases

         11. During the study period planned radiotherapy on target lesion

         12. During the study period, plans to use other antineoplastic therapy

         13. Clinical study on treatment of 30 days beginning period prior to participate in any
             study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang J hua, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang J hua, PD</last_name>
    <phone>13916619284</phone>
    <email>changjianhua@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang J hua, PD</last_name>
      <phone>13916619284</phone>
      <email>changjianhua@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chang Jian Hua</investigator_full_name>
    <investigator_title>attending</investigator_title>
  </responsible_party>
  <keyword>PFS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

